← Eichor
Study identifier: NCT07458425 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

The SENTINL-1 Study: Evaluating Patient-Reported Outcomes of AI-Inferred Lung Cancer Risk

Condition: Lung Cancer  ·  Sponsor: University of Illinois at Chicago

PhaseNA
Planned participants400
Who can joinAll sexes, 50 Years to 80 Years
Healthy volunteersYes

About this study

This is a two-cohort (screen naïve vs screen established), prospective, longitudinal, single-center clinical study design that will provide data to comprehensively evaluate patient-reported outcomes of Artificial Intelligence (AI) based prediction of an individual's risk of developing lung cancer over the next 3 years.

This description comes directly from the study's public registry record.

Talk to the study team

Ameen Salahudeen, MD, PhD  ·  (312) 355-1625  ·  ameen@uic.edu

Erica Seltzer, DrPh, MPH  ·  (312) 413-7432  ·  eseltzer@uic.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of Illinois at ChicagoChicago, Illinois, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07458425